Implementing Pharmacogenetics to Improve Prescribing (IPTIP) V1.0
Research type
Research Study
Full title
Implementing Pharmacogenetics to Improve Prescribing
IRAS ID
305751
Contact name
William Newman
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
How a person responds to a given medicine can vary greatly, with some patients experiencing no effect while others develop severe side effects. This variation has a significant impact on patients and society. Strategies are therefore required to reduce this variability and one approach is to use knowledge of an individual’s genetic information to optimise their treatment, known as pharmacogenomics.
Pharmacogenomic-based prescribing guidelines are available for many medicines. Despite this, implementation of these guidelines in the UK is limited to just a few. This is typically carried out reactively, where single genes are analysed when a specific medication is considered.
An alternative approach would be to use a pre-emptive gene panel. This involves testing individuals for many common pharmacogenetic gene-changes at the same time. This information can then be integrated into a patient’s medical records and used to inform their future treatment.
The Implementing Pharmacogenetics to Improve Prescribing (IPTIP) trial is an NIHR funded study linking a patient's genetic data with prescribing data, to measure how useful pre-emptive pharmacogenetic panel testing would be. Patients attending an outpatient appointment at the Manchester Centre for Genomic Medicine (MCGM), or their family members, will be invited to donate a blood sample for genotyping and consent for researchers to access their prescribing history. A second cohort of patients admitted as inpatients to the acute medical unit (AMU) at Manchester University NHS Trust (MFT) will also be recruited. This will determine the potential value of the approach, in two different care settings, and identify key groups where targeted testing might be more appropriate. Implemented effectively, pharmacogenetics has the potential to improve patient outcomes. The output from the IPTIP trial will inform the development of a local and national pharmacogenetic service.
REC name
London - Fulham Research Ethics Committee
REC reference
22/PR/0012
Date of REC Opinion
25 Feb 2022
REC opinion
Further Information Favourable Opinion